MedTrace Logo

Registre HEAR, Healthcare European Amyloidosis Registry

NCT05101304 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2021-11-01

No results posted yet for this study

Summary

This is a non-interventional, prospective, retrospective, non-comparative, multi-center study.

In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up.

This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis. Three cohorts will be identified: the HEAR (Healthcare European Amyloidosis Registry)-Retrospective Cohort, the HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort and the HEAR (Healthcare European Amyloidosis Registry)-Prospective Cohort.

Conditions

  • Cardiac Amyloidosis

Sponsors & Collaborators

  • Saving Lives Matters

    lead NETWORK

Principal Investigators

  • Thibaud Pr Damy · Henri Mondor University Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101304 on ClinicalTrials.gov